Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
1,845,179
result(s) for
"Prévention"
Sort by:
Suicide psychology
\"Suicide hurts people. People commit suicide as a last resort, no one wants to commit suicide and myths surround suicide. Psychologists know the truth about suicide. What causes it, how to prevent it, the warning signs and more. Tackling this difficult topic, best-selling writer Connor Whiteley explains the fascinating research and tackles the myths of suicide. And why it is critical to talk about. Psychology students, professionals and anyone interested in suicide psychology needs to read this engaging easy-to-understand book.\" -- page [4] of cover.
BOOK
Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections
In an open-label, randomized study involving men who have sex with men, doxycycline use after high-risk sexual exposure reduced the incidence of sexually transmitted infections (chlamydia, gonorrhea, and syphilis).
Journal Article
Glycemia Reduction in Type 2 Diabetes — Microvascular and Cardiovascular Outcomes
In a secondary analysis comparing the effect of insulin glargine, glimepiride, liraglutide, and sitagliptin, added to metformin, on the incidences of microvascular complications and death, no material between-group differences were seen.
Journal Article
The psychology of pandemics : preparing for the next global outbreak of infectious disease
\"Pandemics are large-scale epidemics that spread throughout the world. Virologists predict that the next pandemic could occur in the coming years, probably from some form of influenza, with potentially devastating consequences. Vaccinations, if available, and behavioral methods are vital for stemming the spread of infection. However, remarkably little attention has been devoted to the psychological factors that influence the spread of pandemic infection and the associated emotional distress and social disruption. Psychological factors are important for many reasons. They play a role in nonadherence to vaccination and hygiene programs, and play an important role in how people cope with the threat of infection and associated losses. Psychological factors are important for understanding and managing societal problems associated with pandemics, such as the spreading of excessive fear, stigmatization, and xenophobia that occur when people are threatened with infection. This book offers the first comprehensive analysis of the psychology of pandemics. It describes the psychological reactions to pandemics, including maladaptive behaviors, emotions, and defensive reactions, and reviews the psychological vulnerability factors that contribute to the spreading of disease and distress. It also considers empirically supported methods for addressing these problems, and outlines the implications for public health planning.\"--Back cover.
BOOK
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study
Optimal antithrombotic treatment after transcatheter aortic valve replacement (TAVR) is unknown and determined empirically. The direct factor Xa inhibitor rivaroxaban may potentially reduce TAVR-related thrombotic complications and premature valve failure.
GALILEO is an international, randomized, open-label, event-driven, phase III trial in more than 1,520 patients without an indication for oral anticoagulation who underwent a successful TAVR (ClinicalTrials.govNCT02556203). Patients are randomized (1:1 ratio), 1 to 7days after a successful TAVR, to either a rivaroxaban-based strategy or an antiplatelet-based strategy. In the experimental arm, subjects receive rivaroxaban (10mg once daily [OD]) plus acetylsalicylic acid (ASA, 75-100mg OD) for 90days followed by rivaroxaban alone. In the control arm, subjects receive clopidogrel (75mg OD) plus ASA (as above) for 90days followed by ASA alone. In case new-onset atrial fibrillation occurs after randomization, full oral anticoagulation will be implemented with maintenance of the original treatment assignment. The primary efficacy end point is the composite of all-cause death, stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep venous thrombosis, and systemic embolism. The primary safety end point is the composite of life-threatening, disabling, and major bleeding, according to the Valve Academic Research Consortium definitions.
GALILEO will test the hypothesis that a rivaroxaban-based antithrombotic strategy reduces the risk of thromboembolic complications post-TAVR with an acceptable risk of bleeding compared with the currently recommended antiplatelet therapy–based strategy in subjects without need of chronic oral anticoagulation.
Journal Article
Into the clear blue sky : the path to restoring our atmosphere
In Into the Clear Blue Sky, climate scientist and chair of the Global Carbon Project Rob Jackson explains that we need to redefine our goals. As he argues here, we shouldn't only be trying to stabilize the Earth's temperature at some arbitrary value. Instead, we can restore the atmosphere itself in a lifetime--and this should be our moral duty. Restoring the atmosphere means reducing the amount of greenhouse gases in the air to pre-industrial levels--starting with super-potent methane--to heal the harm we have done. Emissions must be cut, first and foremost. But to safeguard a livable planet for future generations, we must repair the damage we have caused.
BOOK
Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial
Anti-inflammatory therapy with long-term colchicine prevented vascular recurrence in coronary disease. Unlike coronary disease, which is typically caused by atherosclerosis, ischaemic stroke is caused by diverse mechanisms including atherosclerosis and small vessel disease or is frequently due to an unknown cause. We aimed to investigate the hypothesis that long-term colchicine would reduce recurrent events after ischaemic stroke.
We did a randomised, parallel-group, open-label, blinded endpoint assessed trial comparing long-term colchicine (0·5 mg orally per day) plus guideline-based usual care with usual care only. Hospital-based patients with non-severe, non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack were eligible. The primary endpoint was a composite of first fatal or non-fatal recurrent ischaemic stroke, myocardial infarction, cardiac arrest, or hospitalisation (defined as an admission to an inpatient unit or a visit to an emergency department that resulted in at least a 24 h stay [or a change in calendar date if the hospital admission or discharge times were not available]) for unstable angina. The p value for significance was 0·048 to adjust for two prespecified interim analyses conducted by the data monitoring committee, for which the steering committee and trial investigators remained blinded. The trial was registered at ClinicalTrials.gov (NCT02898610) and is completed.
3154 patients were randomly assigned between Dec 19, 2016, and Nov 21, 2022, with the last follow-up on Jan 31, 2024. The trial finished before the anticipated number of outcomes was accrued (367 outcomes planned) due to budget constraints attributable to the COVID-19 pandemic. Ten patients withdrew consent for analysis of their data, leaving 3144 patients in the intention-to-treat analysis: 1569 (colchicine and usual care) and 1575 (usual care alone). A primary endpoint occurred in 338 patients, 153 (9·8%) of 1569 patients allocated to colchicine and usual care and 185 (11·7%) of 1575 patients allocated to usual care alone (incidence rates 3·32 vs 3·92 per 100 person-years, hazard ratio 0·84; 95% CI 0·68–1·05, p=0·12). Although no between-group difference in C-reactive protein (CRP) was observed at baseline, patients treated with colchicine had lower CRP at 28 days and at 1, 2, and 3 years (p<0·05 for all timepoints). The rates of serious adverse events were similar in both groups.
Although no statistically significant benefit was observed on the primary intention-to-treat analysis, the findings provide new evidence supporting the rationale for anti-inflammatory therapy in further randomised trials.
Health Research Board Ireland, Deutsche Forschungsgemeinschaft (German Research Foundation), and Fonds Wetenschappelijk Onderzoek Vlaanderen (Research Foundation Flanders), Belgium.
Journal Article
Younger for life : feel great and look your best with the new science of autojuvenation
From best-selling author and social-media-star doctor comes a step-by-step guide to reversing the effects of aging at any stage in life.
Book
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
In a randomized trial involving patients who had a first stroke from an embolus of unknown source, rivaroxaban at a daily dose of 15 mg did not result in a lower incidence of recurrent stroke than aspirin at a dose of 100 mg. Bleeding rates were higher with rivaroxaban.
Journal Article